1. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients
- Author
-
Francisco García-Río, Antonio Martorell-Calatayud, Luis Hernández Blasco, Joan Dalmau-Arias, Maria Somoza-Gonzalez, Valentín Cabriada-Nuño, Irene Cano-Pumarega, Jorge Abad-Capa, Josep M. Montserrat, David Gozal, Eusebi Chiner Vives, Trinidad Díaz-Cambriles, Miguel Ángel Martínez-García, Eduardo López-Collazo, Francisco Campos-Rodriguez, Ramon Farré, Carolina Cubillos-Zapata, Manuel Sánchez de la Torre, Olga Mediano, Jaime Corral-Peñafiel, Eduardo Nagore, and Isaac Almendros
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Skin Neoplasms ,Cell ,Sentinel lymph node ,Mitosis ,B7-H1 Antigen ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,PD-L1 ,Internal medicine ,mental disorders ,medicine ,Biomarkers, Tumor ,Humans ,Neoplasm Invasiveness ,Obesity ,Neoplasm Metastasis ,Receptor ,Melanoma ,Aged ,Sleep Apnea, Obstructive ,biology ,Anthropometry ,business.industry ,Middle Aged ,Overweight ,medicine.disease ,Immunosurveillance ,medicine.anatomical_structure ,Cross-Sectional Studies ,030228 respiratory system ,ROC Curve ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Cutaneous melanoma ,biology.protein ,Regression Analysis ,Female ,business - Abstract
Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.
- Published
- 2019